These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31566226)

  • 21. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study.
    Kringelbach TM; Glintborg B; Hogdall EV; Johansen JS; Hetland ML;
    BMJ Open; 2018 Feb; 8(2):e019325. PubMed ID: 29391382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system.
    Thomas PWA; West RL; Russel MGVM; Jansen JM; Kosse LJ; Jessurun NT; Römkens TEH; Hoentjen F;
    Pharmacoepidemiol Drug Saf; 2021 Apr; 30(4):520-524. PubMed ID: 33219593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.
    Chen MH; Lee MH; Liao HT; Chen WS; Lai CC; Tsai CY
    Clin Rheumatol; 2018 Feb; 37(2):429-438. PubMed ID: 29307092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
    Wilke T; Mueller S; Lee SC; Majer I; Heisen M
    BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment adherence in rheumatic diseases in the bDMARD era-are we underachieving?
    Oliveira Pinheiro F; Seabra Rato M; Fidalgo I; Brito I
    Z Rheumatol; 2022 Apr; 81(3):245-246. PubMed ID: 35103803
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B.
    King LK; Lee A; Anandacoomarasamy A
    Intern Med J; 2012 May; 42(5):523-31. PubMed ID: 21790927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range.
    Vlieland ND; Gardarsdottir H; Bouvy ML; Egberts TC; van den Bemt BJ
    Rheumatology (Oxford); 2016 Apr; 55(4):704-9. PubMed ID: 26672907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
    Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
    Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.
    Van Herwaarden N; Van Den Bemt BJF; Wientjes MHM; Kramers C; Den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):843-857. PubMed ID: 28686523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research.
    Gasparyan AY; Ayvazyan L; Cocco G; Kitas GD
    Curr Pharm Des; 2012; 18(11):1543-55. PubMed ID: 22364138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
    Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
    J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.
    Nikiphorou E; van der Heijde D; Norton S; Landewé RB; Molto A; Dougados M; Van den Bosch FE; Ramiro S
    Ann Rheum Dis; 2018 Mar; 77(3):405-411. PubMed ID: 29222349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy.
    Bekker CL; Melis EJ; Egberts ACG; Bouvy ML; Gardarsdottir H; van den Bemt BJF
    Res Social Adm Pharm; 2019 Jan; 15(1):100-105. PubMed ID: 29610051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.